Antineoplastic Agents Market Research, 2030
Anti-neoplastic agents are the drugs that prevent the development of neoplasm, a kind of tumor. Antineoplastic agents are also known as anticancer, chemotherapy, chemo, cytotoxic drugs. These agents are available in many forms-some are in the form of pills and others are taken as injections. These agents travel into the human body and destroy the cancerous cells and thus aids in the management of cancer. Many anti-neoplastic agents are available commercially for the therapy of various kinds of cancers including Gleevec, Oncotrex, Cytarabine, Leukeran, Near. These drugs or agents are not only used for different cancers but are used in combination with surgery, radiotherapy, immunotherapy, targeted therapy hormone therapy for many solid tumors, especially metastatic.
Market Highlights
Global Anti-Neoplastic Agents market is expected to project a notable CAGR in 2030.
Global Anti-Neoplastic Agents Market to surpass USD 412.2 million by 2030 from USD 164.67 million in 2020 at a CAGR of 9.6%, in the coming years i.e., 2020-30. The global Anti-Neoplastic Agents market is expected to observe growth in the future owing to increasing cases of cancers and the geriatric population. Change in lifestyle of people and the need for a cost-effective cancer cure are the key factors attributing to the growth of the antineoplastic agent’s market. Additionally, rapid innovations, increasing funding from the government, and favorable reimbursement policies are estimated to fuel the global anti-neoplastic agent market.
Global Anti-Neoplastic Agents Market: Segments
Chemotherapeutic agents’ segment to grow with the highest CAGR during 2020-30
Global Anti-Neoplastic Agents Market is segmented by Type into Chemotherapeutic agents, Biological/immunotherapeutic agent, Personalized medicine, and Others. The chemotherapeutic agents' segment held the largest market share of XX.X% in the year 2019 and is expected to dominate the global market in the coming years. Chemotherapeutic agents are used to preventing the uncontrolled growth and proliferation of cancer cells. Easy accessibility of these drugs is expected to grow the anti-neoplastic market.
Hospital segment to grow with the highest CAGR during 2020-30
Global Anti-Neoplastic Agents Market is segmented by the end user into hospitals, clinics, research institutes, cancer rehabilitation centers, and Others. The hospital segment held the largest market share of XX.X% in the year 2019 and is expected to maintain this trend throughout the forecast period. With the increasing cases of cancer, a vast number of cancer patients are being hospitalized in hospitals every year.
Market Dynamics
Drivers
Growing Cases of Cancer
Growing incidences of cancer and an increasing geriatric population is estimated to grow the anti-neoplastic agent market. With the change in lifestyle of consumers, the risk associated with cancer is increasing. This has attracted the attention of various pharmaceutical companies to get into the anti-neoplastic agent market leading to the growth of the anti-neoplastic agents’ market globally.
Technological Advancements
Several technological advances in the field of personalized medicine offers a huge opportunity to manufacturers of anti-neoplastic agents. Additionally, due to the mounting prevalence of cancer, the multinational firms are increasing investment in cancer research which is projected to boost the global market for anti neo plastic agents.
Restraints
High Development Cost
Development of anti-neoplastic agents involves high costs due to which they are expensive. The high cost of these agents is not affordable by some consumers which are anticipated to limit the growth of global anti neoplastic agents market.
Global Anti-Neoplastic Agents Market: Key Players
- Hoffmann-La Roche
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Amgen Inc.
- Bristol-Myers Squibb Company
- Baxter Healthcare Corporation
- Boehringer Ingelheim GmbH
- Aspen Global Inc.
- Bayer AG
- Teva Pharmaceutical Industries Ltd.
- Johnson & Johnson Pvt. Ltd.
- Merc & Co.
- Pfize Inc.,
- Accord Healthcare, Inc.
- Genentech, Inc.
- Lundbeck LLC
- AbbVie Inc.
- Other Prominent Players
Global Anti-Neoplastic Agents Market: Regions
Global Anti-Neoplastic Agents market is segmented based on regional analysis into five major regions. These include North America, Latin America, Europe, APAC, and MENA. Global Anti-Neoplastic Agents market in North America held the largest market share of XX.X% in the year 2019 owing to high prevalence of malignant neoplasm. Besides, excellent healthcare infrastructure and a number of non-government institutes offering cancer management services in this region are expected to proliferate the global anti-neoplastic market. A disorganized lifestyle coupled with an unhealthy diet is likely to increase the demand for anti-neoplastic agents in the near future.
Global Anti-Neoplastic Agents market is further segmented by region into:
- North America Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – United States and Canada
- Latin America Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – Mexico, Argentina, Brazil, and Rest of Latin America
- Europe Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – United Kingdom, France, Germany, Italy, Spain, Belgium, Hungary, Luxembourg, Netherlands, Poland, NORDIC, Russia, Turkey and Rest of Europe
- APAC Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – India, China, South Korea, Japan, Malaysia, Indonesia, New Zealand, Australia, and Rest of APAC
- MENA Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – North Africa, Israel, GCC, South Africa and Rest of MENA
Global Anti-Neoplastic Agents market report also contains analysis on:
Anti-Neoplastic Agents Market Segments:
- By Product Type
- Chemotherapeutic agents
- Biological/immunotherapeutic agent
- Personalized medicine
- Others
- By Cancer Type
- Blood cancer
- Breast cancer
- Gastrointestinal cancer
- Prostate cancer
- Respiratory/lung cancer
- Other
- By End-user
- Hospitals
- Clinics
- Research institutes
- Cancer rehabilitation centers
- Others
- Anti-Neoplastic Agents Market Dynamics
- Anti-Neoplastic Agents Market Size
- Supply & Demand
- Current Trends/Issues/Challenges
- Competition & Companies Involved in the Market
- Value Chain of the Market
- Market Drivers and Restraints
Frequently Asked Questions (FAQ):
Antineoplastic agents market is valued at approximately USD 140 billion in 2024. Forecasts suggest it could surpass USD 225 billion by 2030, reflecting sustained growth as cancer incidence and treatment innovation rise.
Market is projected to grow at a compound annual growth rate (CAGR) of around 7% to 9% from the mid-2020s into 2030. Faster growth is anticipated in some reports, with a CAGR of around 10% up to 2035, driven by novel therapies and expanding access to oncology care.
Within the market, traditional chemotherapeutic agents remain large in terms of revenue share due to their established use across many cancers. However, biological and immunotherapeutic treatments (such as targeted therapies and immune-checkpoint inhibitors) are growing rapidly and shifting the market dynamics. By end-user, hospitals and oncology treatment centres hold the dominant share since they are primary care settings for cancer drug administration.
Major pharmaceutical and biotech companies are prominent in this market, including global names that have extensive oncology drug portfolios and ongoing R&D in cancer therapies. These firms drive much of the development, approval and commercialization of new antineoplastic agents, especially in targeted and immuno-oncology fields.
Select License Type
.png){kind=icon}
